Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

BRAF binds EGFR, KRAS, and NRAS. 2 / 2

| 2

➶

sparser

"In addition, secondary resistance develops in all patients and is associated with the development of secondary KRAS , NRAS , EGFR or BRAF mutations ( xref , xref , xref )."

28400427

➶

sparser

"We then exploited the GDSC database and found that in a variety of cancer cells, mutations in KRAS, NRAS, and BRAF were associated with resistance to common EGFR inhibitors like Gefitinib and Afatinib, in spite of some mutations that did not pass false discovery rate (FDR), possibly due to complexity of genetic background throughout so many cancer types ( xref ; xref )."

25894462

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...